Journal of Pharmaceutical Sciences and Drug Development aims to broadcast scholarly research contributions pertaining to drug discovery, drug delivery, targeted drug delivery therapy, drug abuse, and drug effect. The Journal caters to the updated information requirements of pharmacy students, health care providers as well as medical professionals. The journal invites unique compositions in light of rules and additionally applicatory parts of drug toxicology, drug abuse, drug mechanism, and effective medication for diseases. Furthermore, the journal also focusses on the worldwide dissemination of information pertaining to the development of novel methods of envenomation.
Journal Highlights:
• Journal h-index: 2
• Journal Cite Score: 0.11
• Journal Impact Factor: 0.36
• Indexing: All published articles of this journal are included in the indexing and abstracting coverage of Google Scholar, Advanced Science Index, Access to Global Online Research in Agriculture (AGORA), Academic Keys, and Academic Journals Database.
New trends and genuine publications do not focus on the impact factor but focus on the publisher’s quality and less time-consuming process for their publication of the article.
A big journal has a high impact factor and h-index but do not process the articles for years and the research work remains in draft and outdated.
Journal Membership Plan
Journal Benefits:
• Journal of Pharmaceutical sciences and drug development also provides the pre-print facilities at a very reasonable and affordable amount of @19 Euros/copy.
• On the bulk of E-print copies we provide a huge discount to support eminent researchers from all over the world.
• We promote the researchers and their work through our social media platform as well as at our National and International conferences.
Journal Duty
Our journal strictly follows the peer-review process and provides the best quality of the publication. We believe if a journal follows all the rules from accepting articles to publishing them and if it takes 30-45 days for publishing an article it means they are genuine and respect your work.
Recent Publishing Article: Recently we publish the article of an eminent Author
• “Fascicular Left Ventricular Tachycardia Associated with Energy Drink Consumption”
The article describes Idiopathic Fascicular Ventricular Tachycardia (IFVT) of the left ventricle as an infrequent form of Ventricular Tachycardia (VT), usually occurring in patients without structural heart disease, sensitive to verapamil and whose mechanism is reentry using the specific conduction system of the left ventricle. The most frequent are VTs that compromise the posterior fascicle, constituting 90% of cases. Energy drinks have been associated with supraventricular and ventricular cardiac arrhythmias in young patients without known heart disease. We present the case of a 36-year-old male patient, with no known medical history, who after ingesting an energy drink (VOLT®) suddenly presented a non-radiated precordial pain and palpitations, and was translated to the emergency room, where an Electrocardiogram (ECG) was performed showing a VT with wide QRS and right bundle branch block morphology, with an axis, deviated to the left, it was decided to administer verapamil 5 mg intravenously, achieving reversion to sinus rhythm, the progressive elevation of troponin T was observed, for which cardiac catheterization was performed without evidence of lesions in the coronary arteries. The presence of structural heart disease was ruled out with cardiac magnetic resonance imaging. The diagnosis of FVT triggered by the consumption of an energy drink in a structurally healthy heart was established, treatment with bisoprolol 2.5 mg orally daily was indicated, caffeine intake was prohibited, and a schedule of outpatient controls was established.
• “Determination of Teicoplanin via Spectrophotometric and High-Performance Liquid Chromatographic Methods”
The article describes Two methods that have been suggested for the quantitative estimation of Teicoplanin (TCP) as pure and in its dosage forms. The first: spectrophotometric method included the reaction of TCP with Fe (III) in an acidic medium and the liberated Fe (II) coupled with potassium ferricyanide, the reaction needs heating for 30 minutes at 40o C to form a Prussian blue complex. The maximum absorption of the resulting product was measured at 767 nm with a molar absorptivity of 6.39 x 105 l.mol-1.cm-1.Linearity according to Beer's law is in the concentration range from 0.4 to 7.5μg. Ml-1. The relative standard deviation% (RSD %) of the method was better than 2.9 % . The LOD and LOQ values have been calculated and are equal to 0.1541 and 0.5136 μg.ml-1 respectively. The second method was reverse phase high performance liquid chromatographic (RP-HPLC) using a C18 (150 mm length x 4.6 mm ID, 5 μm) column with 20 μl injection volume. The mobile phase was consisting of methanol: Acetonitrile in the ratio (90:10 V /V), and the flow rate was maintained at 2.5 ml.min-1.TCP was monitored using Agilent 1200 series equipped with a photodiode array detector. Different analytical parameters were determined according to International Conferences on Harmonization (ICH). Linearity was observed in the concentration range from 4 to 200. The suggested methods are simple and sensitive and the RP-HPLC can be used as a quality-control tool for routine quantitative analysis of TCP in the pharmaceutical dosage form.
Accepting articles from the relevant field
• Drug Delivery system
• Targeted Drug Delivery
• Pharmacology
• Pharmacovigilance
• Computer-aided drug design
• Dose-response
• Drug delivery system
• Pharmacodynamics
• Pharmacogenetics
• Pharmacogenomics
• Pharmacokinetics
• Pharmacometrics
• Pharmacoproteomics
• Pharmacoresistance
• Prodrug
• Cosmetology
Article Processing charges – 850 Euros (per article)
Submission link- https://www.scholarscentral.org/submissions/pharmaceutical-sciences-drug-development.html
Further laboratories and research institutes can also contact us for collaborations and membership. Reach Us:-
WhatsApp. +441704335730
Email Id: - pharmachemistry@scienceresearchpub.org
Comments